Expanded Access Program for Patients With Migraine

Status No longer available

Clinical Trial Summary

This expanded access program is designed to make fremanezumab available to patients with EM or CM who have successfully completed (per protocol) Teva-sponsored Study TV48125-CNS-30051 or TV48125-CNS-30068 ("prior studies") until fremanezumab becomes commercially available in their country.

Clinical Trial Description

Fremanezumab is indicated for patient suffering from Episodic or Chronic Migraine. Patients interested in received expanded access to Fremanezumab must meet the following conditions: 1. Have participated in, and successfully completed, one of the two clinical studies TV48125-CNS-30051 (HALO) or TV48125-CNS-30068 (FOCUS) 2. Participated from one of the following countries: 1. For HALO: Canada, Czech Republic, Spain or Finland 2. For FOCUS: Czech Republic, Spain, Finland, Germany, Sweden, Denmark, Netherlands, Italy, France or Belgium Eligible patients should contact their study physician to request expanded access. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03539393
Study type	Expanded Access
Source	Teva Branded Pharmaceutical Products R&D, Inc.
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06192173` - Patent Foramen Ovale Closure in Migraine
Completed	`NCT05525611` - Cabergoline as a Preventive Treatment for Chronic Migraine	N/A
Recruiting	`NCT03832998` - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	Phase 3
Enrolling by invitation	`NCT04196933` - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma	N/A
Not yet recruiting	`NCT06428838` - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context	Phase 3
Completed	`NCT06304675` - Manageable Environmental Factors in Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05517200` - Pilot Study for a Machine Learning Test for Migraine
Completed	`NCT04179474` - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine	Phase 1
Recruiting	`NCT04603976` - Registry for Migraine - Clinical Core	Phase 4
Completed	`NCT03597529` - CHOCOlate MeLatonin for AdolescenT MigrainE	Phase 2
Completed	`NCT04197349` - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman	Phase 1
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting	`NCT05064371` - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan	Phase 3
Suspended	`NCT04069572` - Vibratory Stimulation for the Treatment of Chronic Pain	N/A
Not yet recruiting	`NCT04859374` - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach	N/A
Not yet recruiting	`NCT03083860` - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.	N/A
Completed	`NCT02905227` - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder	Phase 1
Enrolling by invitation	`NCT02532023` - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients	Phase 4
Completed	`NCT02108678` - One-Day Intervention for Depression and Impairment in Migraine Patients	N/A